Atezolizumab + Bevacizumab + Y-90 TARE for Liver Cancer

Recruiting in Palo Alto (17 mi)

+5 other locations

Overseen byAiwu R He, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Aiwu Ruth He, MD

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.

Eligibility Criteria

Adults with advanced, inoperable liver cancer (HCC) who haven't had prior systemic therapy. They must have a good performance status and liver function (Child-Pugh score A or selected B7), no history of certain severe health conditions, not be pregnant or breastfeeding, and willing to use contraception. Candidates should understand the study procedures and agree to follow them.

Inclusion Criteria

My liver cancer diagnosis is confirmed by lab tests.

I am not eligible for or have refused a liver transplant.

Documented virology status of HIV

See 15 more

Exclusion Criteria

I have an autoimmune disease treated with medication in the last 2 years.

I still have side effects from previous cancer treatments.

Pregnant or breastfeeding

See 29 more

Treatment Details

Interventions

Atezolizumab (Monoclonal Antibodies)
Bevacizumab (Monoclonal Antibodies)
Y-90 TARE (Radiopharmaceuticals)

Trial OverviewThis phase II trial is testing if adding atezolizumab and bevacizumab after Y-90 TARE treatment improves outcomes for patients with unresectable HCC compared to Y-90 TARE alone. Participants are randomly assigned to one of these two approaches in an open-label setting across multiple centers.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm BExperimental Treatment3 Interventions

TARE then Bevacizumab and Atezolizumab

Group II: Arm AActive Control1 Intervention

TARE alone

Atezolizumab is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Tecentriq for: